한빛사논문
- 조회350
In Ha Kim, Geun Dong Lee, Sehoon Choi, Hyeong Ryul Kim, Yong-Hee Kim, Dong Kwan Kim, Seung-Il Park, Jae Kwang Yun*
Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, Ulsan University College of Medicine, Seoul, Republic of Korea.
*Corresponding Author: Jae Kwang Yun, MD, PhD
Abstract
Introduction: The aim of this study was to validate the discriminatory ability and clinical utility of the N descriptor of the newly proposed 9th edition of the TNM staging system for lung cancer in a large independent cohort.
Methods: We retrospectively analyzed patients who underwent curative surgery for non-small cell lung cancer (NSCLC) between January 2004 and December 2019. The N descriptor of patients included in this study was retrospectively reclassified based on the 9th edition of the TNM classification. Survival analysis was performed using the log-rank test and Cox proportional hazard model to compare adjacent N categories.
Results: A total of 6649 patients were included in this study. The median follow-up period was 54 months. According to the newly proposed 9th edition N classification, 5573 (83.8%), 639 (9.6%), 268 (4.0%), and 169 (2.5%) patients were classified into the clinical N0, N1, N2a, and N2b categories and 4957 (74.6%), 744 (11.2%), 567 (8.5%), and 381 (5.7%) were classified into the pathologic N0, N1, N2a, and N2b categories, respectively. The prognostic differences between all adjacent clinical and pathologic N categories were highly significant in terms of both overall survival (OS) and recurrence-free survival (RFS).
Conclusions: We validated the clinical utility of the newly proposed 9th edition N classification for both clinical and pathologic stages in NSCLC. The new N classification showed clear prognostic separation between all categories (N0, N1, N2a, and N2b) in terms of both OS and RFS.
논문정보
- Research article
- 2024년 04월 (BRIC 등록일 2024-04-15)
- 국내 연구진
- 의약학 > 종양의학
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기
